© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 81417 pertains to the re-evaluation of previously obtained exome sequencing, which is a specialized form of molecular genetic testing. This testing focuses on the exome, the portion of the genome that contains the sequences of protein-coding DNA, which are crucial for understanding genetic disorders. Exome sequencing is particularly valuable in cases where patients present with multiple anomalies and a genetic disorder is suspected but not yet identified. By analyzing the exome, healthcare professionals can identify disease-causing genetic variants and gene targets that may be responsible for the patient's condition. This method is cost-effective and allows for the examination of approximately 180,000 exomes, covering about 85% of mutations that lead to heritable diseases. The testing process involves obtaining a blood sample through a separate venipuncture procedure, which is then analyzed using Next Generation Sequencing (NGS) technology. This advanced technique enables the detection of various genomic variants, including single nucleotide variants (SNVs), small DNA insertions or deletions (indels), copy number variants (CNVs), and other structural variants (SVs). The re-evaluation indicated by code 81417 is particularly relevant when there is updated knowledge regarding genetic conditions or when assessing unrelated conditions or syndromes that may not have been previously considered.
© Copyright 2025 Coding Ahead. All rights reserved.
The indications for performing the procedure associated with CPT® Code 81417 include the following:
The procedure for CPT® Code 81417 involves several key steps, which are detailed as follows:
After the completion of the exome sequencing and analysis, the patient may require follow-up consultations to discuss the results. The healthcare provider will review the findings with the patient, explaining any identified genetic variants and their potential implications for diagnosis, treatment, or management of the condition. Additionally, if new information or updated knowledge regarding genetic conditions becomes available, further evaluations or testing may be recommended. It is essential for the healthcare team to provide appropriate counseling and support to the patient and their family, particularly if the results indicate a heritable condition that may affect other family members.
Short Descr | EXOME RE-EVALUATION | Medium Descr | EXOME RE-EVAL OF PREVIOUSLY OBTAINED EXOME SEQ | Long Descr | Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 |
Date
|
Action
|
Notes
|
---|---|---|
2022-01-01 | Note | Guidelines changed. |
2015-01-01 | Added | Added |
Get instant expert-level medical coding assistance.